Rucaparib (AG-014699,PF-01367338)

Catalog No.S1098

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Price Stock Quantity  
USD 134 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rucaparib (AG-014699,PF-01367338) Chemical Structure

Rucaparib (AG-014699,PF-01367338) Chemical Structure
Molecular Weight: 421.36

Validation & Quality Control

6 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Rucaparib (AG-014699,PF-01367338) is available in the following compound libraries:

PARP Inhibitors with Unique Features

  • Selective PARP Inhibitors

    AG-14361 PARP1-selective, Ki<5 nM. UPF 1069 PARP2-selective, IC50=0.3 μM.

  • Most Potent PARP Inhibitor

    MK-4827 (Niraparib) PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.

  • PARP Inhibitor in Clinical Trial

    Iniparib (BSI-201) Phase III for solid tumors.

  • Newest PARP Inhibitor

    PJ34 HCl PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Product Information

  • Compare PARP Inhibitors
    Compare PARP Products
  • Research Area

Product Description

Biological Activity

Description Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Targets PARP [1]
(Cell-free assay)
IC50 1.4 nM(Ki)
In vitro Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
BT-474MUTGeY5kfGmxbjDBd5NigQ>?NWPoeII3OC5zL{GvOVAxNzFyMECgcm0>M4nuZ4lvcGmkaYTzJHBCWlBiYXP0bZZqfHliYYSgd5RienSrbnegZ49v[2W{boTyZZRqd25ib3[gOVAxKG6PM4LsOlI2OTJ6NEW1
BT474M3vFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\lfFU2ODBibl2=NGTPWZcyOOLCk{G1xsBlNWT5bFlqemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>?NYnGdmpNOjVzMki0OVU>
SKBR3NWrUXIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml73OVAxKG6PMWmxNQKBmzF3wrDkMmjrdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=>MXWyOVEzQDR3NR?=
AU565MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfqOVAxKG6PNFfxV|IyOOLCk{G1xsBlM3r0TpJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk>NH\Td3YzPTF{OES1OS=>
EFM192AMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\oZVUxOCCwTR?=MVOxNQKBmzF3wrDkNUXUbI93emWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>?NFflPFkzPTF{OES1OS=>
MDA-MB-231MUjGeY5kfGmxbjDBd5NigQ>?NVHJNpNjOTBxMkCvOFAh|ryPM2LERlI1KGh?NXnCUnZ[cW6lcnXhd4V{KHBvQVvUJIxmfmWuczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=MVGyOFQzODF3Mh?=
MDA-MB-231MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MYWwMlEuPDBizszNM1ryN|I1KGh?NHP4WldKSzVy4pEJQgKBkTF5Lke3xsDPxE1?Ml7QNlQ1OjBzNUK=
MDA-MB-231NXzOe25[SXCxcITvd4l{KEG|c3H5MXixNE8zOC92MDFOwG0>NGe2WGEzPCCqMl;NbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?=NV\HdII{OjR2MkCxOVI>
MDA-MB-231MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITLZYkyOC9{MD:0NEDPxE1?M4PqfFI1KGh?M3e2[IJtd2OtczDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKGmwIFeyM20heGijc3W=MWqyOFQzODF3Mh?=
H460M4\tVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWm0NFAhdk1?MXSyOOKhcA>?MkC1bY5kemWjc3XzJINmdGy3bHHyJJJi\Gmxc3Xud4l1cX[rdIm=NYnuUlJnOjR2MUG2NVE>
A549 NUDGNXo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mke2OFAxKG6PNWGwbZhbOjUEoHi=NGXjdpNqdmO{ZXHz[ZMh[2WubIXsZZIhemGmaX;z[Y5{cXSrdnn0fS=>M2r0U|I1PDFzNkGx
DT40Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXzWIM2UUN3ME2yNUBvVQ>?MmTBNlQ{PTZ6MUO=
DU145MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLMTWM2OD1zODDuUS=>MWiyOFM2PjhzMx?=
COLO704NYHSTHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLCTWM2OD1{LkWyJOKyKDBwNkeg{txOMVuyN|czQTRyMh?=
OVMANAbNWDOUXRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm[0TWM2OD1{LkW4JOKyKDBwM{ig{txOMV2yN|czQTRyMh?=
OV177MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33XOGlEPTB;Mj63PEDDuSByLkexJO69VQ>?M1HLVlI{PzJ7NECy
OAW28MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELQdJNKSzVyPUOuOlEhyrFiMD6yPEDPxE1?NXm1RY9qOjN5Mkm0NFI>
OVSAHOMoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfR[25KSzVyPUOuOlQhyrFiMD6zN{DPxE1?M4j0VVI{PzJ7NECy
OVKATENXHaN2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTNwNkSgxtEhOS55OTFOwG0>MnH2NlM4Ojl2MEK=
OVCAR3M4XvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTNwN{SgxtEhOC52MDFOwG0>MYWyN|czQTRyMh?=
PEO14NXHLVWdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjjbXVDUUN3ME2zMlg1KMLzIECuO|Yh|ryPM1PxTFI{PzJ7NECy
A2780MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\MSndVUUN3ME2zMlk1KMLzIECuNlUh|ryPM{LaZlI{PzJ7NECy
OVTOKONHrIOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfWNpcyUUN3ME20MlE1KMLzIEGuOVMh|ryPMV[yN|czQTRyMh?=
KURAMOCHIbM4C1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLJfpVWUUN3ME20MlM1KMLzIECuNlkh|ryPNYT4UpRuOjN5Mkm0NFI>
TOV21GM3\yUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYD6Z3NiUUN3ME21MlA4KMLzIEGuN|Ah|ryPNHLObpczOzd{OUSwNi=>
OVISENVjZZWhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTVwNkigxtEhOC5{MzFOwG0>NHLWb3UzOzd{OUSwNi=>
KKMoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXziOpp5UUN3ME22MlE2KMLzIEGuOFIh|ryPMlS2NlM4Ojl2MEK=
RMUGSNHjt[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXzUmZKSzVyPUeuNFMhyrFiMT64N{DPxE1?M4LtSlI{PzJ7NECy
PEO6MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXqRlB6UUN3ME23MlA3KMLzIECuO|Qh|ryPM2WxOFI{PzJ7NECy
OVCA429NIm1UXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRThwMkmgxtEhOS54NDFOwG0>MX6yN|czQTRyMh?=
OV167Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRThwM{OgxtEhOS5zODFOwG0>MlroNlM4Ojl2MEK=
RMG1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTlwM{KgxtEhOi5|NjFOwG0>NHLNUYozOzd{OUSwNi=>
OVCAR5NF;hb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzLNZc2UUN3ME25MlUxKMLzIEKuOVkh|ryPNF6z[24zOzd{OUSwNi=>
EFO21NH6zRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrUcJY5UUN3ME25MlkzKMLzIEGuPFch|ryPNVz3fIxbOjN5Mkm0NFI>
ES2MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDuZ4hsUUN3ME2xNE4yOiEEsTCxMlI{KM7:TR?=NVftXoQ3OjN5Mkm0NFI>
Tyk-nuNFTtTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjOXJhlUUN3ME2xNE4zOCEEsTCxMlEzKM7:TR?=NWrzepBuOjN5Mkm0NFI>
CAOV3M4HoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTFyLkO3JOKyKDBwOEeg{txOMk\WNlM4Ojl2MEK=
OV207NV\FTWNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{j5UWlEPTB;MUKuNlchyrFiMD6zNkDPxE1?MWGyN|czQTRyMh?=
HEYMlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULoXmp1UUN3ME2xN{4xOSEEsTCwMlc2KM7:TR?=MV:yN|czQTRyMh?=
DOV13M2DTRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRjF3IN88US=>M3XvWlI{PzJ7NECy
EFO27MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHO4TYxKSzVyPkG1JO69VQ>?MVuyN|czQTRyMh?=
HEY C2M4\ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3yT|dkUUN3ME6xOUDPxE1?MlXwNlM4Ojl2MEK=
KOC-7ccNUXWc5RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRjF3IN88US=>NFXHOpIzOzd{OUSwNi=>
MCASbMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLne4FKSzVyPkG1JO69VQ>?M{HVflI{PzJ7NECy
OAW42MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Xm[WlEPTB-MUWg{txONXvSfIRVOjN5Mkm0NFI>
OV2008NXP2R2UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vPe2lEPTB-MUWg{txOMXKyN|czQTRyMh?=
OV90MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzvbVVNUUN3ME6xOUDPxE1?M4j3O|I{PzJ7NECy
OVCA420bMmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUnJR|UxRjF3IN88US=>NYq1WmRNOjN5Mkm0NFI>
OVCA432NFfJbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{fSbGlEPTB-MUWg{txOM2e2clI{PzJ7NECy
PEA2M1\VTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRjF3IN88US=>NV7xV3hJOjN5Mkm0NFI>
SKOV3MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRjF3IN88US=>MXiyN|czQTRyMh?=
TOV112DMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknnNE0{KM7:TR?=NH;OVVdKSzVyPkG1JO69VQ>?NWDYT4sxOjN5Mkm0NFI>
C4-2MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvJfHF{OC1|IN88US=>NW\YUJoxOTRiZB?=MYXEUXNQMUfk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6M3nSeFI{PTZ3MkS0
PC3NFv2TpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPWR2VpOC1|IN88US=>NE\Wb4syPCCmM2PLemROW09?NFrrUnhl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7NVPDWIplOjN3NkWyOFQ>
DU145NFLtSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrpNE0{KM7:TR?=NF\HVIcyPCCmNXy1UWVKTE2VTx?=NY[xTVFG\GWlcnXhd4V{KGOxbH;ufUBvfW2kZYKg[I9{\SCmZYDlcoRmdnSueR?=NEHEVpYzOzV4NUK0OC=>
VCaP NYXxeVg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;2fFU6OC1|IN88US=>NEjN[ZQyPCCmM2XldWROW09?MY\k[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6NFTNdHczOzV4NUK0OC=>
LNCaP NX\Mc3drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIjaT3oxNTNizszNM{fidVE1KGR?NHToWFdFVVORM1XCZYRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl?M{fQbVI{PTZ3MkS0
MDA-MB-468NYL0fG5SS2WubDDWbYFjcWyrdImgRZN{[Xl?NEHSUYVKSzVyPUmuO{DPxE1?NU\aOlc3OjJ4N{ixOlE>
MDA-MB-231MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>MnTVTWM2OD1zMzFOwG0>M1HzdVIzPjd6MU[x
Cal-51M2PudmNmdGxiVnnhZoltcXS7IFHzd4F6NF7NZ|FKSzVyPUiuOkDPxE1?NGXBbFQzOjZ5OEG2NS=>

... Click to View More Cell Line Experimental Data

In vivo Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]
Features The first PARP inhibitor used in clinical trials combined with temozolomide.

Protocol(Only for Reference)

Kinase Assay: [1]

Ki Determination Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
Inhibition of PARP activity Inhibition of PARP activity in 5 × 103 D283Med cells is measured using various concentrations of Rucaparib (0-1 μM), compared with DMSO-only. Maximally stimulated PARP activity is measured in samples of permeabilised cells by immunologica

Cell Assay: [4]

Cell lines D425Med, D283Med and D384Med cells
Concentrations 0.4 μM
Incubation Time 3 or 5 days
Method Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.

Animal Study: [4]

Animal Models CD-1 nude mice bearing established D283Med xenografts
Formulation Normal saline
Dosages 1 mg/kg
Administration One or four daily by i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Thomas HD, et al. Mol Cancer Ther, 2007, 6(3), 945-956.

[2] Kotz, J. SciBX 5(13); doi:10.1038/scibx.2012.323.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02740712 Recruiting Neoplasms Clovis Oncology, Inc. March 2016 Phase 1
NCT02505048 Not yet recruiting Metastatic Breast Cancer UNICANCER|Clovis Oncology, Inc.|Fondation ARC March 2016 Phase 2
NCT02042378 Completed Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Clovis Oncology, Inc. April 2014 Phase 2
NCT01968213 Active, not recruiting Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer Clovis Oncology, Inc. January 2014 Phase 3
NCT01891344 Active, not recruiting Ovarian Cancer|Epithelial Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer Clovis Oncology, Inc.|Foundation Medicine September 2013 Phase 2

view more

Chemical Information

Download Rucaparib (AG-014699,PF-01367338) SDF
Molecular Weight (MW) 421.36
Formula

C19H18FN3O.H3PO4

CAS No. 459868-92-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 84 mg/mL (199.35 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 8-fluoro-5-(4-((methylamino)methyl)phenyl)-3,4-dihydro-2H-azepino[5,4,3-cd]indol-1(6H)-one phosphoric acid

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PARP Products

  • G007-LK

    G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.

  • NU1025

    NU1025 is a potent PARP inhibitor with IC50 of 400 nM.

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Olaparib (AZD2281, Ku-0059436)

    Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.

    Features:A potent PARP inhibitor (currently in late stage clinical trials).

  • Veliparib (ABT-888)

    Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

    Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.58 nM in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

    Features:Most potent and selective PARPi reported thus far.

  • Iniparib (BSI-201)

    Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.

  • PJ34 HCl

    PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

    Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).

  • AG-14361

    AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

    Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.

  • A-966492

    A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

    Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Recently Viewed Items

Tags: buy Rucaparib (AG-014699,PF-01367338) | Rucaparib (AG-014699,PF-01367338) supplier | purchase Rucaparib (AG-014699,PF-01367338) | Rucaparib (AG-014699,PF-01367338) cost | Rucaparib (AG-014699,PF-01367338) manufacturer | order Rucaparib (AG-014699,PF-01367338) | Rucaparib (AG-014699,PF-01367338) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us